About ACI

Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS).

ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration. 

ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein.  It is in preclinical development for the treatment of ALS.  ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.

Our History

Alpha Cognition's history

Corporate

Read More

Latest News

View All

TSX-V: ACI

15 min delay
Last$20.05
Change$-0.21
Open20.41
Vol1685357
High20.78
Low20.05
Stock Information